DaVita HealthCare Partners is a medical care facilities business based in the US. DaVita HealthCare Partners shares (DVA) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $142.62 – an increase of 0.76% over the previous week. DaVita HealthCare Partners employs 76,000 staff and has a trailing 12-month revenue of around $12.8 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $142.62 |
|---|---|
| 52-week range | $131.44 - $179.60 |
| 50-day moving average | $146.49 |
| 200-day moving average | $153.60 |
| Wall St. target price | $164.57 |
| PE ratio | 13.1911 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $10.73 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $141.57 from 2025-05-05
| 1 week (2025-04-29) | 0.02% |
|---|---|
| 1 month (2025-04-07) | -3.44% |
| 3 months (2025-02-07) | -18.44% |
| 6 months (2024-11-07) | -5.85% |
| 1 year (2024-05-07) | 2.82% |
|---|---|
| 2 years (2023-05-05) | 60.02% |
| 3 years (2022-05-06) | 37.50% |
| 5 years (2020-05-06) | 71.91% |
Valuing DaVita HealthCare Partners stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DaVita HealthCare Partners's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DaVita HealthCare Partners's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, DaVita HealthCare Partners shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
DaVita HealthCare Partners's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9392. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DaVita HealthCare Partners's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DaVita HealthCare Partners's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.7 billion.
The EBITDA is a measure of a DaVita HealthCare Partners's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $12.8 billion |
|---|---|
| Operating margin TTM | 13.74% |
| Gross profit TTM | $4.2 billion |
| Return on assets TTM | 7.15% |
| Return on equity TTM | 51.74% |
| Profit margin | 7.31% |
| Book value | $1.50 |
| Market Capitalization | $10.9 billion |
TTM: trailing 12 months
We're not expecting DaVita HealthCare Partners to pay a dividend over the next 12 months.
DaVita HealthCare Partners's shares were split on a 2:1 basis on 8 September 2013 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DaVita HealthCare Partners shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DaVita HealthCare Partners shares which in turn could have impacted DaVita HealthCare Partners's share price.
Over the last 12 months, DaVita HealthCare Partners's shares have ranged in value from as little as $131.44 up to $179.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DaVita HealthCare Partners's is 1.044. This would suggest that DaVita HealthCare Partners's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits